CliniMARK

About CliniMARK

THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.

Thousands of circulating proteins have been shown to be hallmarks of emerging disease, response to treatment, or a patients’ prognosis. The identification of these small molecule biomarkers holds a great promise for significant improvement of personalized medicine based on simple blood tests. For instance, diagnosis and prognosis with biomarkers (e.g. carcinoembryonic antigen (CEA)) has significantly improved patient survival and decreased healthcare costs in colorectal cancer patients. Unfortunately, despite significant investments to increase the number of biomarker studies, only ~150 out of thousands of identified biomarkers have currently been implemented in clinical practice.

Keywords

• Biomarker Clinical Feasibility Study Design
• Capacity Building
• Implementation Of Bbp Guidelines: Demonstrator Project Copd Group Details Working Group 4
• Selection And Analytical Validation Of Biomarker Detection Technique(S)

Address

• Headquarters

  Wytemaweg 803015CN RotterdamZuid-Holland, Netherlands